573 related articles for article (PubMed ID: 31654287)
21. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
[TBL] [Abstract][Full Text] [Related]
22. Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling.
Shum S; Shen DD; Isoherranen N
Drug Metab Dispos; 2021 Nov; 49(11):1003-1015. PubMed ID: 34407992
[TBL] [Abstract][Full Text] [Related]
23. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
Khalil F; Läer S
AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
[TBL] [Abstract][Full Text] [Related]
25. Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions.
Statelova M; Holm R; Fotaki N; Reppas C; Vertzoni M
AAPS J; 2020 Sep; 22(6):126. PubMed ID: 33000297
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
[TBL] [Abstract][Full Text] [Related]
27. Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example.
Feng S; Shi J; Parrott N; Hu P; Weber C; Martin-Facklam M; Saito T; Peck R
Clin Pharmacokinet; 2016 Jul; 55(7):823-832. PubMed ID: 26715215
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of a Pragmatic PBPK Modeling Approach: Towards Model-Informed Dosing in Pediatric Clinical Care.
van der Heijden JEM; Freriksen JJM; de Hoop-Sommen MA; van Bussel LPM; Driessen SHP; Orlebeke AEM; Verscheijden LFM; Greupink R; de Wildt SN
Clin Pharmacokinet; 2022 Dec; 61(12):1705-1717. PubMed ID: 36369327
[TBL] [Abstract][Full Text] [Related]
29. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.
Maharaj AR; Barrett JS; Edginton AN
AAPS J; 2013 Apr; 15(2):455-64. PubMed ID: 23344790
[TBL] [Abstract][Full Text] [Related]
30. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I
Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923
[TBL] [Abstract][Full Text] [Related]
32. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
34. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.
Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D
CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992
[TBL] [Abstract][Full Text] [Related]
35. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
[TBL] [Abstract][Full Text] [Related]
36. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
37. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.
Yang F; Tong X; McCarver DG; Hines RN; Beard DA
J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):485-518. PubMed ID: 16758333
[TBL] [Abstract][Full Text] [Related]
38. Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics.
Yu Y; DuBois SG; Wetmore C; Khosravan R
AAPS J; 2020 Jan; 22(2):31. PubMed ID: 31975150
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.
Naga D; Parrott N; Ecker GF; Olivares-Morales A
Mol Pharm; 2022 Jul; 19(7):2203-2216. PubMed ID: 35476457
[TBL] [Abstract][Full Text] [Related]
40. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
